UY35091A - Formulaciones de liberacion modificada para oprozomib - Google Patents

Formulaciones de liberacion modificada para oprozomib

Info

Publication number
UY35091A
UY35091A UY0001035091A UY35091A UY35091A UY 35091 A UY35091 A UY 35091A UY 0001035091 A UY0001035091 A UY 0001035091A UY 35091 A UY35091 A UY 35091A UY 35091 A UY35091 A UY 35091A
Authority
UY
Uruguay
Prior art keywords
oprozomib
release formulations
modified release
formulations
release pharmaceutical
Prior art date
Application number
UY0001035091A
Other languages
English (en)
Inventor
Jumaa Mouhannad
Muchamuel Tony
Bejugam Naveen
Wong Hansen
Christopher J Kirk
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of UY35091A publication Critical patent/UY35091A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

La memoria descriptiva presenta formulaciones farmacéuticas de liberación modificada (por ejemplo, formulaciones farmacéuticas de liberación ampliada; por ejemplo, formas farmacéuticas sólidas, por ejemplo, comprimidos) que son útiles para la administración oral de oprozomib, o una de sus sales farmacéuticamente aceptables, a un sujeto animal o humano así como a métodos de preparar y utilizar dichas formulaciones
UY0001035091A 2012-10-24 2013-10-22 Formulaciones de liberacion modificada para oprozomib UY35091A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261717975P 2012-10-24 2012-10-24
US201261721244P 2012-11-01 2012-11-01
US201361793087P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
UY35091A true UY35091A (es) 2014-05-30

Family

ID=50485877

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035091A UY35091A (es) 2012-10-24 2013-10-22 Formulaciones de liberacion modificada para oprozomib

Country Status (24)

Country Link
US (2) US9295708B2 (es)
EP (1) EP2912025A4 (es)
JP (1) JP6505604B2 (es)
KR (1) KR20150070406A (es)
CN (1) CN104968650A (es)
AP (1) AP3681A (es)
AR (1) AR093126A1 (es)
AU (1) AU2013334258A1 (es)
BR (1) BR112015008572A2 (es)
CA (1) CA2888039A1 (es)
CL (1) CL2015001085A1 (es)
CR (1) CR20150266A (es)
EA (1) EA201590797A1 (es)
HK (2) HK1208222A1 (es)
IL (1) IL238244A0 (es)
IN (1) IN2015DN03921A (es)
MX (1) MX2015005069A (es)
PE (1) PE20151051A1 (es)
PH (1) PH12015500823A1 (es)
SG (1) SG11201502849XA (es)
TN (1) TN2015000135A1 (es)
TW (1) TW201422255A (es)
UY (1) UY35091A (es)
WO (1) WO2014066681A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
CA2988918A1 (en) 2015-06-19 2016-12-22 Biotie Therapies, Inc. Controlled-release tozadenant formulations
CN105949279A (zh) * 2016-04-27 2016-09-21 浙江大学 蛋白酶体抑制剂Oprozomib及其类似物的制备方法
IL263771B2 (en) * 2016-06-29 2023-09-01 Kezar Life Sciences Preparation process of immunoproteasome epoxytone peptide inhibitor and its precursors
JP2019529458A (ja) 2016-09-21 2019-10-17 小野薬品工業株式会社 オプロゾミブ用の即放性製剤
WO2018112078A1 (en) 2016-12-14 2018-06-21 Amgen Inc. Gastro-retentive modified release dosage forms for oprozomib and process to make thereof
EP3694878A1 (en) 2017-09-14 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer
CN110357940A (zh) * 2019-08-02 2019-10-22 苏州艾和医药科技有限公司 奥普佐米合成工艺研究
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
AU4499697A (en) 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
MXPA03007043A (es) * 2001-02-12 2003-11-18 Wyeth Corp Nueva sal de succinato de o-desmetil-venlafaxina.
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
KR101274417B1 (ko) * 2005-11-09 2013-06-17 프로테올릭스, 인코퍼레이티드 효소 저해를 위한 화합물
CA2632962A1 (en) * 2006-01-10 2007-07-19 Yasuhiro Takeda Sustained release preparation and method for production thereof
WO2008140782A2 (en) 2007-05-10 2008-11-20 Proteolix, Inc. Compounds for enzyme inhibition
MY173938A (en) * 2007-10-04 2020-02-27 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
TWI504598B (zh) * 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑

Also Published As

Publication number Publication date
IN2015DN03921A (es) 2015-10-02
CL2015001085A1 (es) 2015-08-28
EP2912025A4 (en) 2016-06-08
US20160213610A1 (en) 2016-07-28
TN2015000135A1 (en) 2016-10-03
HK1208222A1 (en) 2016-02-26
AP3681A (en) 2016-04-19
AP2015008387A0 (en) 2015-04-30
WO2014066681A1 (en) 2014-05-01
BR112015008572A2 (pt) 2017-07-04
JP6505604B2 (ja) 2019-04-24
HK1215709A1 (zh) 2016-09-09
JP2015535255A (ja) 2015-12-10
US20140113855A1 (en) 2014-04-24
MX2015005069A (es) 2015-07-17
PH12015500823A1 (en) 2015-06-22
IL238244A0 (en) 2015-06-30
CN104968650A (zh) 2015-10-07
PE20151051A1 (es) 2015-08-03
CA2888039A1 (en) 2014-05-01
EA201590797A1 (ru) 2016-02-29
AR093126A1 (es) 2015-05-20
US9295708B2 (en) 2016-03-29
EP2912025A1 (en) 2015-09-02
KR20150070406A (ko) 2015-06-24
TW201422255A (zh) 2014-06-16
CR20150266A (es) 2015-08-14
SG11201502849XA (en) 2015-05-28
AU2013334258A1 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
CR20150326A (es) Inhibidores de autotaxina
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
UY31747A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
MX2013006591A (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
UY32487A (es) Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
CO6430456A2 (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
CY1118032T1 (el) Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα
ES2446643R1 (es) Composiciones farmacéuticas combinadas y su uso para preparar un medicamento destinado al tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
ECSP12012236A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
CO6640305A2 (es) Elaboración de gránulos sin activos y tabletas que comprenden los mismos
BR112018071370A2 (pt) composições farmacêuticas orais de mesalazina
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CR20140293A (es) Preparaciones que comprenden emodepsido amorfo
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210617